Skip to main content

ALDX

Stock
Health Care
Biotechnology

Performance overview

ALDX Price
Price Chart

Forward-looking statistics

Beta
1.59
Risk
82.77%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Company info

SectorHealth Care
IndustryBiotechnology
Employees14
Market cap$229.3M

Fundamentals

Enterprise value$154.9M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity24.48

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.97
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$5M
Avg trading volume (10 day)$6M
Put-call ratio

Macro factor sensitivity

Growth+0.9
Credit+7.6
Liquidity+0.1
Inflation-4.1
Commodities-0.7
Interest Rates-3.0

Valuation

Dividend yield0.00%
PEG Ratio-7.05
Price to sales
P/E Ratio-7.05
Enterprise Value to Revenue
Price to book4.06

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns

The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.'s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease.

Benzinga (April 3, 2025)
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?

Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.

Zacks Investment Research (December 9, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free